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Malaria during pregnancy is a major health problem for Afri-
can women. The disease is caused by Plasmodium falciparum
malaria parasites, which accumulate in the placenta by adhering
to chondroitin sulfate A (CSA). The interaction between in-
fected erythrocytes and the placental receptor is mediated by a
parasite expressedproteinnamedVAR2CSA.Avaccineprotect-
ing pregnant women against placental malaria should induce
antibodies inhibiting the interaction between VAR2CSA and
CSA. Much effort has been put into defining the part of the 350
kDa VAR2CSA protein that is responsible for binding. It has
been shown that full-length recombinant VAR2CSA binds spe-
cifically to CSA with high affinity, however to date no sub-frag-
ment of VAR2CSA has been shown to interact with CSA with
similar affinity or specificity. In this study, we used a biosensor
technology to examine the binding properties of a panel of trun-
cated VAR2CSA proteins. The experiments indicate that the
core of the CSA-binding site is situated in three domains,
DBL2X-CIDRPAM and a flanking domain, located in the N-ter-
minal part of VAR2CSA. Furthermore, recombinant VAR2CSA
subfragments containing this region elicit antibodies with high
parasite adhesion blocking activity in animal immunization
experiments.
Carbohydrates, or glycans, are highly diverse in structure and
biological function and are expressed by virtually all mamma-
lian cells. Many microorganisms, i.e. viruses, bacteria, and pro-
tozoa, have evolvedmechanisms to establish infection by inter-
acting with glycans on the host cell surface (1), and the
Plasmodium parasites causing malaria are no exception. Of the
different Plasmodium species that can infect humans, Plasmo-
dium falciparum is by far the most virulent form and was the
cause of 89%of all deaths due tomalaria infection in theAfrican
region in 2008 (the World Malaria Report 2009, WHO).
A number of important potential P. falciparum vaccine tar-
gets have been defined as glycan-binding proteins or lectins, e.g.
circumsporozoite protein, which interacts with highly sulfated
heparan sulfate proteoglycans (HSPG)3 during sporozoite inva-
sion of the liver, and the EBA-175 surface antigen thatmediates
merozoite invasion of erythrocytes through the interaction
with sialic acid on glycophorin A (2). In addition to these pro-
teins, VAR2CSA, a unique member of the P. falciparum eryth-
rocyte membrane protein 1 (PfEMP1) family has been charac-
terized as a lectin with binding preference for a low-sulfated
form of chondroitin sulfate A (CSA) anchored to proteoglycans
(CSPG) in placental tissue (3–7). VAR2CSA, is a large multido-
main antigen expressed on the surface of P. falciparum-in-
fected erythrocytes (IEs) where it mediates sequestration of the
IEs to the placenta (8). This placental sequestration causes pla-
cental malaria (PM), a major cause of mother and offspring
morbidity such as severe maternal anemia, low birth weight,
and stillbirth (9).
Pregnantwomen and their unborn children are the victims of
this severe disease, and it should be feasible to protect them by
a vaccine. This is based on the fact that immunity to PM in
malaria-endemic regions is acquired as a function of parity
(10–12) and the main antigen-mediating sequestration,
VAR2CSA, has been found in all P. falciparum genomes stud-
ied. When looking at PfEMP1 sequence variation VAR2CSA
appears as an unusually conserved PfEMP1 proteinwith as high
as 75–83% amino acid identity between variants (13). The large
molecularweight ofVAR2CSAmakes production of full-length
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recombinant protein for vaccine use difficult. The ideal sce-
nario for vaccine development is to define a region of the
VAR2CSA, which induces antibodies that can abrogate placen-
tal adhesion of the full repertoire of genetically different P. fal-
ciparum parasites. The consequences of vaccinating to induce
VAR2CSA-specific antibodies that are opsonising but not able
to block parasite sequestration are not known but could poten-
tially worsen the parasite-induced inflammation in the
placenta.
Considering the size and the complex structure it is essential
to define smaller regions of VAR2CSA that can be included in a
vaccine, the obvious approach being to define the glycan-bind-
ing site. However, this has not been straightforward and the
molecular mechanism underlying the interaction between
VAR2CSA and CSA remains unresolved. This is in part due to
the difficulties in analyzing protein-glycan binding in vitro,
which easily gives rise to false positive identification of nonspe-
cific glycan-binding proteins because of the large impact of low
affinity charge-charge interactions (14).
To date, vaccine development has relied on the production of
a large panel of various recombinant VAR2CSA-derived pro-
tein fragments and analysis of their capacity to induce antibod-
ies in animals that can block adhesion of IEs to CSA in vitro.
This trial and error approach has generated several potential
vaccine antigens (15–17) although the capacity of these pro-
teins to specifically bind CSA is questionable (18). Neverthe-
less, understanding the mode of CSA binding of VAR2CSA is
likely to be essential for the optimal design of a vaccine against
PM.
An important breakthrough in this respect was recently
made when the full-length ectodomain of VAR2CSA was suc-
cessfully expressed as a recombinant protein and for the first
time high affinity binding, within the nanomolar range, was
attained when binding this complete ectodomain of VAR2CSA
to CSA (6, 7). Based on a few truncated proteins and a compact
low-resolution structure of VAR2CSA, Srivastava et al. (7) pro-
posed that the entire ectodomain is required for a specific high
affinity CSA interaction. This would explain the reported
observations that no single recombinant VAR2CSA domain
binds with high affinity to CSA (18, 19).
In this study we have systematically analyzed recombinant
fragments of VAR2CSA for affinity to CSA and defined two
overlapping protein constructs that possess the same binding
properties as the full-length VAR2CSA ectodomain. Specific
binding activity locates to the four N-terminal domains,
DBL1X-ID1, DBL2X, CIDRPAM, and DBL3X. A major part of
the interaction seems to be conferred by proteins encompass-
ing the DBL2X-CIDRPAM region, however an additional
domain is required to obtain high affinity binding. Importantly
animal-induced antibodies against a recombinant protein
encoding the entire binding region effectively block adhesion of
IEs to CSA.
EXPERIMENTAL PROCEDURES
P. falciparum Cultures—Parasite cultures of the FCR3 strain
were grown as previously described (20). In brief, parasiteswere
maintained in culture using 5% hematocrit of blood (human
blood group 0) in parasite medium consisting of RPMI 1640
supplemented with 25 mM sodium bicarbonate (Sigma-
Aldrich), 0.125 g/ml gentamicin, 0.125 g/ml Albumax II
(Invitrogen), and 2% normal human serum. Parasites were
repeatedly panned on BeWo cells to select for VAR2CSA
expression as described (21). All parasite isolates were tested
mycoplasma negative and were regularly genotyped using
nestedGLURP (glutamate-rich protein) andMSP-2 (merozoite
surface protein 2) primers in a single PCR step.
Cloning and Protein Expression—Subgenetic fragments were
amplified from the codon-optimized FCR3 var2csa gene (Gen-
BankTM Accession No. GU249598) or FCR3 genome DNA and
cloned into the baculovirus vector pAcGP67-A (BD Biosci-
ences)modified to contain aV5 epitope upstreamof aHis tag at
the C-terminal end (Table 1). Linearized Bakpak6 Baculovirus
DNA (BD Biosciences) was co-transfected with pAcGP67-A
into Sf9 insect cells for the generation of recombinant virus
particles. High-Five cells grown in suspension in 400ml serum-
free medium (10486, GIBCO) were infected with 10 ml of the
second amplification of recombinant virus particles when the
cell density had reached 0.9–1  106 cells/ml. The culture
supernatant containing the secreted recombinant protein was
harvested 26 h after virus infection and filtered (0.2 m) before
dialysis.
Protein Purification and SDS-PAGE—Filtrated cell culture
supernatant was dialyzed using an A¨KTA cross-flow (GE
Healthcare) in 10 mM NaH2PO4 (pH 7.4) and 500 mM NaCl,
yielding a final volume of 45 ml. The retentate was filtered (0.2
m) and imidazole (pH 7.4, Sigma-Aldrich) was added to the
sample to give a final imidazole concentration of 15 mM before
loading onto a 1-ml HisSelect column (H8286, Sigma-Aldrich).
The bound protein was eluted with 10 mM NaH2PO4 (pH 7.4),
500 mM NaCl, and 500 mM imidazole. When required, protein
samples were subsequently purified by size-exclusion chroma-
tography on a HiLoad 16/60 SuperdexTM 200 column (GE
Healthcare) using a buffer of 20 mM Tris (pH 8.0) and 200 mM
NaCl, to obtain monomers for the quartz crystal microbalance
measurements. Protein purity and formation of disulfide
TABLE 1
Primers for cloning of var2csa fragments that were expressed as pro-
teins and analysed for receptor binding activity
Constructs were cloned from the codon-optimized FCR3 var2csa gene (Gen-
BankTM accession no. GU249598) into the pAcGP67-A vector (BD Biosciences)
using either EcoRI/NotI or BamHI/NotI restriction sites. FV2, full-length ectodo-
main of VAR2CSA without N-terminal segment; NTS, N-terminal segment; DBL,
Duffy binding-like domain; ID, interdomain; CIDRPAM, cysteine-rich interdomain
region specific for VAR2CSA and pregnancy-associated malaria (PAM).
PROTEIN Forward primer Reverse primer
FV2 CCACAGCGATAGCGGCAAG CGAAGGGCTCGTCGGCCTGGGG
NTS-FV2 CATGGACAGCACCAGCACA CCTGGGGTGGCAGATCGTC
NTS-DBL4 ATGGACAGCACCAGCACA TGTCCAGGGGGTACAGCTT
NTS-DBL3X ATGGACAGCACCAGCACA CGGCATTGTTGTACTTATA
NTS-DBL2Xa ATGGATAGTACAAGCACT ATCCTATATCAATTAAGTG
ID1-DBL4 CTGAGCTTCATCCTGAAC TGTCCAGGGGGTACAGCTT
ID1-DBL3X CTGAGCTTCATCCTGAAC CGGCATTGTTGTACTTATA
DBL2X-DBL4 CTGACCAACGGCTACAAG TGTCCAGGGGGTACAGCTT
DBL2X-DBL3Xb CTGACCAACGGCTACAAG CGGCATTGTTGTACTTATA
DBL3Xa ACCAATATTAATAAAAGTGAA CAGCATTATTATATTTGTA
DBL2Xa TTAACGAATGGTTATAAATGC ATCCTATATCAATTAAGTG
DBL1X-CIDRPAMc CACAGCGATAGCGGCAAG TCTTGTTGATATTGGTGTCGGT
DBL2X-CIDRPAM CTGACCAACGGCTACAAG TCTTGTTGATATTGGTGTCGGT
aGenome DNA from the FCR3 parasite was used as cloning template.
b Could not be expressed as a soluble protein.
c Previously known as ID2, but is called CIDRPAM according to the updated no-
menclature recently described (37).
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bridges were verified by SDS-PAGE using NuPage Novex Tris-
acetate mini gels (Invitrogen) and NuPage Tris-acetate SDS
running buffer. A high molecular weight protein marker
(LC5699, Invitrogen) was used as a standard. Around 1–2g of
protein was mixed with SDS loading dye, with and without
reducing agent (50 mM DTT), and heated at 75 °C for 10 min
prior to loading onto the gel. Gels were run at 140 V for 1 h
and 30 min and finally stained using BioSafeTM Coomassie
(Bio-Rad).
Animal Immunizations and IgG Purification—All proce-
dures regarding animal immunizations complied with European
and national regulations. Wistar rats received 30 g of recombi-
nant protein in Freund’s complete adjuvant, and were boosted
three timeswith 15g of protein in Freund’s incomplete adjuvant
at 3-week intervals. Antibodies against the recombinant proteins
were generated in rats as described in Nielsen et al. (15). Immune
sera from all immunizations were collected 8 days after the final
boost andused for IgGpurification.RecombinantGammaBindTM
G type 2 coupled to SepharoseTM 4B (GEHealthcare) was used to
purify IgG according to the manufacturer’s instructions. In brief,
0.5–1 ml of filtered (0.2 m) rat serum was diluted 1:1 in 20 mM
NaH2PO4 (pH7.0) andmanually passed throughacolumnpacked
with Sepharose (300 l of Sepharose per ml of serum). The same
serumwas passed through the column ten times and thenwashed
with 20 mM NaH2PO4 (pH 7.0) followed by a wash with 100 mM
citric acid (pH4.0). Finally, bound IgGwas elutedwith 9ml of 100
mM citric acid (pH 2.7) and collected in tubes with 3.6 ml of 1 M
Tris (pH9.0). Purified IgGwas concentrated and stored in aliquots
at80 °C.
Quartz Crystal Microbalance Assay—CSPG from bovine
articular cartilage (decorin) was used as a source of CSA.
Importantly, IE adhesion to decorin can be abrogated by soluble
CSA aswell as by chondroitinase treatment of the decorin. This
CSPG has either a CSA chain or a dermatan sulfate chain
attached to the protein core. By using a CSA-specific antibody,
it was determined that the decorin used carried a CSA side
chain in addition we confirmed that VAR2CSA expressing par-
asites could not adhere to dermatan sulfate (data not shown).
All biosensor measurements were performed using an Attana
A100 (Attana AB). Gold-plated, 10 MHz, AT-cut quartz crys-
tals which were pretreated to generate a polystyrene coating
were purchased from Attana AB. The surface was housed in a
cylindrical flow chamber with a volume of 1.25 l. All buffers
and solutions were sterile filtered (0.2 m) before use. A solu-
tion of 100g/ml CSPG (D8428, Sigma-Aldrich), or 100g/ml
HSPG (H4777, Sigma-Aldrich) in PBS was allowed to adsorb to
the surface at room temperature for 30 min. Following this, the
surface was washed and then blockedwith PBS containing 0.1%
Ig-free BSA (BSA-50, Rockland) at room temperature for 30
min. The assays were performed at a flow rate of 25 l/min at
25 °C, and with PBS as running buffer. After the baseline stabi-
lized, buffer injections were performed to show that the base
line was unaffected by the injection process. The data were
processed to line up the curves according to injection time and
the curves were fitted to either a simple 1:1 binding model
allowing for mass transport limitations using software package
Scrubber 2 (BioLogic Software Pty Ltd, Campbell, Australia), or
a heterogeneity model using ClampXP (Tom Morton and
David Myszka, version 3.50) if a simple 1:1 model fit gave an
error ofmore than 10% of the parameter value. kon and koff were
given by the curve fitting and the KDwas calculated by dividing
the koff by the kon. The software use the Levenberg-Marquardt
method for nonlinear sum of squares error minimization.
The data were processed and curves fitted to either a simple
1:1 bindingmodel using software package Scrubber 2 (BioLogic
Software Pty Ltd, Campbell, Australia), or a heterogeneity
model using ClampXP (Tom Morton and David Myszka, ver-
sion 3.50). This software uses the Levenberg-Marquardt
method for nonlinear sum of squares error minimization.
Solid Phase Binding Assay—To remove the CSA chains from
the protein core, CSPG (40 g) was digested with 25.6 mU
chondroitinase ABC (C2905, Sigma-Aldrich) in enzyme buffer
(50mMTris, 50mM sodium acetate, pH 8.0) in a total volume of
200 l. The reaction was incubated overnight at 37 °C with
gentle rotation. Digested CSPG was subsequently dialyzed
against PBS. The final product was analyzed by ELISA using a
mAb (MAB2030, Chemicon) targeting chondroitinase ABC-
digested CSA and by SDS-PAGE as described above, to verify
that the CSA chains had been removed and that the protein
core was intact after enzyme treatment (data not shown).
Falcon microtiter plates (351172, BD Biosciences) were pre-
incubated with either 3 g/ml CSPG, 3 g/ml enzyme treated
CSPG or 3g/ml HSPG for 2 h at 37 °C. Following coating with
proteoglycan, the wells were blocked with TSM binding buffer
(20 mM Tris, 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2, 0.05%
Tween-20, and 1% BSA, pH 7.4 at 25 °C) for 2 h at 37 °C. A
2-fold dilution series (1.56–100 nM) of each protein was pre-
pared in TSM binding buffer, added in triplicates to the wells
and incubated for 1 h at 37 °C with gentle shaking. After wash-
ing three times in TSM washing buffer (20 mM Tris, 150 mM
NaCl, 2 mM CaCl2, 2 mM MgCl2, 0.05% Tween-20, pH 7.4 at
25 °C), an anti-V5-HRP antibody (R96125, Invitrogen) diluted
1:3000 in binding buffer was added to each well and incubated
for 1 h at 37 °C with gentle shaking. The assay was finalized by
washing three times and developed using 100 l per well of
o-phenylenediamine substrate (DAKO) for 15 min. Absor-
bance was measured at 490 nm after quenching the reaction
with 100 l of 2.5 M H2SO4.
Flow Cytometry—Antibody binding to the native VAR2CSA
protein expressed on the surface of FCR3 IEs was measured by
flow-cytometry (FCM). Briefly, the parasite culture was
enriched for late trophozoite and schizont stage IEs in a strong
magnetic field (MACS, Miltenyi). Aliquots of 2  105 IEs in a
total volume of 100 l of PBS with 2% FCS were labeled by
antibodies in a final concentration of 0.5 mg/ml purified IgG.
The cells were washed three times in a total volume of 200l of
PBS with 2% FCS and subsequently exposed to a final concen-
tration of 2 g/ml ethidium bromide and a 1:100 dilution of
FITC labeled secondary antibody specific for rat IgG (62-9511,
Invitrogen). As a negative control, IEswere incubated bothwith
IgG from rats immunized with an irrelevant antigen (CIDR1
from VAR4 3D7) and with secondary antibodies alone. Data
from 5000 IEs (ethidium bromide positive) was collected on
a FC500 flow cytometer (Beckman Coulter). The median FITC
fluorescence intensity was determined using Winlist Software
(Verity Software House).
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Parasite Binding Assays—To analyze the capacity of IgG to
inhibit parasite binding to CSA we used a 96- well plate format
and a robot-standardized washing method. Briefly, tritium-la-
beled late trophozoite and schizont stage IEs wereMACS puri-
fied (Miltenyi). A total of 2  105 IEs in 100 l were added in
triplicates to wells coated with 2 g/ml CSPG. Following incu-
bation with different concentrations of IgG for 90 min at 37 °C,
unbound IEs were washed away by resuspension performed by
a pipetting robot (Beckman Coulter). The proportion of adher-
ing IEs was determined by liquid scintillation counting on a
TopcountNXT (Perkin-Elmer). TheCSA specificity of IE bind-
ing to CSPG was verified by abrogating the binding by 100
g/ml soluble CSA (Sigma-Aldrich) and by chondroitinase
ABC treatments (Sigma-Aldrich) (data not shown).
RESULTS
Production of Recombinant Proteins—All constructs in this
study were expressed in baculovirus-infected insect cells as sol-
uble proteins secreted into the cell culture supernatant (Fig. 1).
All proteins formed the expected intra-molecular disulfide
bridges, which were confirmed by the difference in mobility
when comparing reduced and non-reduced protein samples by
SDS-PAGE (Fig. 1). Several proteins formed high-molecular
complexes detected by non-reduced SDS-PAGE, probably due
to the formation of inter-molecular disulfide bonds between
unpaired cysteines because these complexes were readily
reduced to monomeric protein using DTT (data not shown).
Thus to obtain monomeric proteins most recombinant con-
structs were further purified by size-exclusion chromatography
prior to receptor binding analysis. Only the main peak fraction
from the size-exclusion chromatography was used for receptor
binding assays, however when analyzing these peak fractions by
SDS-PAGE it was noted that small molecular bands appeared
for some proteins (Fig. 1). This could be degradation products
following the size-exclusion chromatography or artifacts from
the SDS-PAGE.
Kinetic Analysis of VAR2CSA Proteins Binding to CSPG—
The full-length ectodomain of VAR2CSA from two genetically
different parasite lines (FCR3 and 3D7) have previously been
shown to bind specifically to CSPG with nanomolar affinity (6,
7). These affinity measurements were obtained using a surface
plasmon resonance technology (Biacore). Here we analyzed the
full-length VAR2CSA, with (NTS-FV2) and without (FV2) the
N-terminal segment (NTS) as well as truncatedVAR2CSApro-
teins, for affinity to CSPG using a quartz crystal microbalance
biosensor (Attana A100) with the aim of mapping the minimal
binding region of VAR2CSA from FCR3. Association and dis-
sociation data for each proteinwas collected at different protein
concentrations to allow an accurate estimation of the binding
affinity (dissociation equilibrium constant, KD). Sensorgrams
and corresponding association rate constant (kon), dissociation
rate constant (koff) and KD values for each protein are shown in
Fig. 2. The measurements obtained with the Attana biosensor
confirm the previously published results (6), i.e. full-length
VAR2CSA binds to CSPG with nano-molar affinity, and it is
apparent that the absence or presence of the NTS region does
not significantly change the affinity to CSPG (KD is 0.54 nM for
FV2 and 2.9 nM for NTS-FV2, Fig. 2, A and B, respectively). By
systematic truncation of the VAR2CSA ectodomain we find
that the functional CSA-binding site of VAR2CSA is located in
the N-terminal part of the protein and the core of the binding
region consists of two domains, DBL2X and CIDRPAM (Fig. 2
and Table 2). This region binds with relatively high affinity to
CSPG (KD of 40 nM) and the data fitted to a 1:1 binding model
(Fig. 2L). AlthoughDBL2X-CIDRPAM alone binds to CSPG, the
interaction with CSPG is reinforced by a flanking domain in
either end of the construct, and the proteins DBL1X-CIDRPAM
and ID1-DBL3X bind to CSPGwith aKD of 2.7 nM and 0.86 nM,
respectively (Fig. 2, K andG), similar to that observed for NTS-
FV2 and FV2. The DBL3X domain alone binds weakly and het-
erogeneously toCSPG (Fig. 2I), consistentwith results obtained
in a previous study (19). Likewise, binding of DBL2X toCSPG is
of weak affinity and heterogeneous consistent with previously
published (18) (Fig. 2J). The NTS-DBL2X protein does not
interact with CSPG (Fig. 2E) even though this construct
includes DBL2X, which binds weakly as a single domain, most
likely because the DBL2X residues mediating the interaction to
CSPG are not exposed in this protein. The CIDRPAM domain
FIGURE 1. Coomassie-stained SDS-PAGE of recombinant VAR2CSA pro-
teins. All constructs were produced in baculovirus-infected insect cells and
purified as soluble proteins on a HisSelect column. 1–2 g of protein was
mixed with SDS loading dye, with and without reducing agent (50 mM DTT).
A, lane 1: reducedNTS-FV2; lane 2: non-reducedNTS-FV2; lane 3: reduced FV2;
lane 4: non-reduced FV2; lane 5: reduced NTS-DBL4; lane 6: non-reduced
NTS-DBL4. B, lane 1: reduced NTS-DBL3X; lane 2: non-reduced NTS-DBL3X;
lane 3: reduced NTS-DBL2X; lane 4: non-reduced NTS-DBL2X; lane 5: reduced
ID1-DBL3X; lane 6: non-reduced ID1-DBL3X. C, lane 1: reduced DBL2X-DBL4;
lane 2: non-reduced DBL2X-DBL4; lane 3: reduced DBL2X; lane 4: non-re-
duced DBL2X; lane 5: reduced DBL3X; lane 6: non-reduced DBL3X. D, lane 1:
reduced ID1-DBL4; lane 2: non-reduced ID1-DBL4; lane 3: reduced DBL1X-
CIDRPAM; lane 4: non-reduced DBL1X-CIDRPAM; lane 5: reduced DBL2X-
CIDRPAM; lane 6: non-reduced DBL2X-CIDRPAM.M, protein marker. Black stars
indicate correct protein size when multiple bands are visible.
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and the DBL2X-DBL3X protein were not analyzed because of
difficulties in producing these proteins.
Analysis of VAR2CSA Proteins Binding to HSPG—Placental
IEs seem to selectively adhere to the CSA chains of CSPG and
not to other glycosaminoglycans (4, 22), and it has previously
been shown that FCR3 IEs expressing VAR2CSA on the cell
surface do not bind to HSPG (18). To assess whether this re-
ceptor specificity also applies for recombinant full-length
VAR2CSA and the minimal CSA binding region defined in the
N-terminal, a number of selected proteins were analyzed for
binding toHSPGby both quartz crystalmicrobalancemeasure-
ments (Fig. 3) and by a solid phase binding assay (Fig. 4). High
affinity binding of full-length VAR2CSA (NTS-FV2) and trun-
cated VAR2CSA proteins was detected to HSPG. However, for
several recombinant proteins it was not possible to fit a 1:1
binding model to the HSPG affinity curves and it is apparent
that the peak response of HSPG binding is considerably lower
than the CSPG response, indicating that only a fraction of the
VAR2CSA proteins interact with HSPG (Fig. 3). Affinity mea-
surements usingVAR2CSAproteins not purified by size-exclu-
sion chromatography show that aggregated protein has amuch
higher tendency to bind to HSPG (data not shown). The peak
response for the coreDBL2X-CIDRPAMwas low and at a similar
level for both CSPG and HSPG binding (Fig. 3D). This lack of
specificity of DBL2X-CIDRPAM was also confirmed in the solid
phase binding assay (Fig. 4E).
Overall, the solid phase binding experiments corroborate the
kinetic data by showing high CSPG specificity for all VAR2CSA
proteins containing the CSA binding core DBL2X-CIDRPAM
flanked by either the DBL1X in the N-terminal end or the
DBL3Xdomain in theC-terminal end (Fig. 4). Limited amounts
of the ID1-DBL4 protein restricted the specificity analysis to
the solid phase binding assay. Similarly, there was not enough
protein of ID1-DBL3X to analyze HSPG binding. None of the
proteins tested appeared to bind the protein core of CSPG, as
demonstrated by their lack of binding to chondroitinase ABC-
treated CSPG (Fig. 4).
Analysis of VAR2CSA-specific Antibodies for Inhibition of
Parasite Adhesion to CSPG—From the point of view of vaccine
development it is important to analyze the ability of induced
VAR2CSA-specific antibodies to block adhesion of IEs to CSA.
Furthermore, suchdatamayprovide additional informationabout
the receptor binding site. IgG induced by VAR2CSA constructs
were analyzed by FCM for reactivity with native VAR2CSA pro-
tein on the surface of homologous FCR3 IEs. All the VAR2CSA-
specific IgG purifications were positive in the FCM analysis
althoughtoavaryingdegree (Fig.5).Asexpected, themultidomain
proteins clearly induced a higher FCM antibody titer.
The purified IgG was subsequently assessed for the ability to
inhibit adhesion of FCR3 IEs to CSPG in an inhibition binding
assay. Each IgG was analyzed in a dilution series as follows: 0.5,
0.1, 0.02, and 0.004 mg/ml (Fig. 6). As previously shown anti-
bodies specific forDBL4-ID4 (15), which is our leading vaccine
candidate, and full-length VAR2CSA including the NTS region
(NTS-FV2) (6) are both highly inhibitory (complete inhibition
at an IgG concentration of 0.5 mg/ml and 90% inhibition at
0.1 mg/ml). In line with this, antibodies against the five domain
construct NTS-DBL4 inhibit parasite adhesion to CSPG with
the same efficiency as the DBL4-ID4-specific IgG. Interest-
ingly, antibodies specific for theNTS-DBL3X construct are also
potent inhibitors (90% inhibition at 0.5 mg/ml) despite the
finding that IgG induced by the individual domains DBL1X,
DBL2X, andDBL3X do not exhibit any inhibitory activity when
pooled.
Although antibodies against the FV2 construct (lacking the
NTS region) completely abolish parasite binding at 0.5 mg/ml
of IgG, these are not as inhibitory as the NTS-FV2 antibodies at
lower IgG concentrations. This observation is in some respects
surprising since the FV2 protein binds, if not better than, at
least as strongly as theNTS-FV2 toCSPG.This implies a proper
folding of these two proteins thus displaying the same epitopes.
However, it is possible that this discrepancy is due to variations
in the animal immunizations or IgG preparation because the
FCM results also show a difference in parasite surface reactivity
between these two full-length constructs. Adhesion of the
FCR3 IEs to CSPG was unaffected by IgG specific for the con-
trol protein (CIDR1 from VAR4 3D7).
DISCUSSION
Specific accumulation of P. falciparum-infected erythro-
cytes in the developing placenta causes the severe malaria syn-
drome named placental malaria. The main placental receptor
for parasite binding are the CSA chains of CSPG (22).The
unique sulfation pattern of the placental CSA (4, 5) probably
FIGURE 2. Kinetic analysis of VAR2CSA proteins binding to CSPG. A quartz crystal microbalance biosensor (Attana A100) was used for the kinetic analyses.
Sensorgrams show VAR2CSA fragments binding to immobilized CSPG as a response (in Hertz) as a function of time (in seconds). Both the association and
dissociation phase are shown. Black lines represent data, and red lines represent fitted curves attained by a 1:1 bindingmodel. The concentrations of VAR2CSA
proteins for individual curves are shown, and the insets list kon, koff, and the calculated KD. The protein tested is indicated in the upper left corner of each
sensorgram.
TABLE 2
CSPG binding analysis of recombinant VAR2CSA proteins
The kinetic analyses were performed using a quartz crystal microbalance biosensor
(Attana A100). Estimated KD values are based on a 1:1 binding model (see Fig. 2 for
fitted binding curves) for each protein interacting with CSPG.
a Kinetic data could not be obtained due to lack of binding to CSPG.
b Both DBL2X and DBL3X bind heterogeneously and with weak affinity to CSPG,
therefore the binding strength could not be satisfactory calculated.
c Binding of DBL2X-CIDRPAM is not specific for CSPG, and binding to HSPG is of
similar affinity.
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explains the exclusively placental trophism.TheVAR2CSApro-
tein is themajor parasite-encoded antigen associatedwith placen-
tal parasite adhesion and is the leadingPMvaccine candidate. Sev-
eral different regions of VAR2CSA have been proposed as
responsible for the binding to CSA (23, 24), and it was recently
suggested that the entire ectodomain is required for a high affinity
interaction (7). In this study, we aimed to define the exact mini-
mumCSA-binding region of the VAR2CSA protein.
Proteins of the PfEMP1 family consist of several highly cys-
teine-rich domains, which form a complex structure held
together by a number of intramolecular disulfide bridges.
Because of the many disulfide bonds, the production of these
FIGURE 3. Comparing VAR2CSA binding to CSPG and HSPG using a biosensor. A quartz crystal microbalance biosensor (Attana A100) was used for the
kinetic analyses. Sensorgrams show VAR2CSA fragments binding either to immobilized CSPG or immobilized HSPG. The graphs show response (in Hertz) as
a function of time (in seconds). Both the association and dissociation phase are shown. Black lines represent data, and red lines represent fitted curves
attained by either a 1:1 binding model or a heterogeneity model. Insets show kon and koff as well as KD calculated from these. Furthermore, the insets
show the maximum response obtained with the given concentration (peak response) and the type of fit used. The protein in flow is listed in the upper
left corner of each sensorgram.
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molecules as correctly folded protein has been, and remains,
a challenge. VAR2CSA is the only PfEMP1 molecule in
which the entire extracellular region has been successfully
produced as a recombinant protein, and this has only been
done in an insect cell expression system (6) and in HEK293
cells (7). In this study, all VAR2CSA proteins were expressed
in baculovirus-infected insect cells and successful formation
of intramolecular disulfide bridges was confirmed by re-
duced and non-reduced SDS-PAGE.
Our protein-glycan binding results provide compelling evi-
dence that the receptor binding site of VAR2CSA from the
FCR3 parasite lies within the N-terminal region, i.e. DBL1X-
ID1-DBL2X-CIDRPAM-DBL3X, within which the binding core
consists of DBL2X-CIDRPAM (summarized in Table 2). The
DBL2X-CIDRPAM protein does not possess all the elements
required for a specific CSA interaction of high affinity, but
when this core assembles with either the DBL1X domain in the
N-terminal end or the DBL3X domain in the C-terminal end,
the CSA binding strength is increased to the level of the full-
length protein and the specificity seems to be retained. It is
possible that these flanking domains have a stabilizing effect on
the binding corewithout directly participating in theCSAbind-
ing. Alternatively, DBL1X and DBL3X exhibit residues that are
directly involved in the CSA binding, which is enhanced by the
presence of these domains. We have previously shown that the
DBL2X single domain does bind to some extend to CSA in a
solid phase binding assay but with low specificity (18). This is
supported by the present data showing that the affinity of the
DBL2X protein to CSA is low.
The CSA binding properties of the DBL3X domain has been
extensively studied (19, 25–27), but these results have not con-
formed to the expected specificity and affinity of the interaction
between VAR2CSA and CSA. Although the DBL3X domain
alone binds with weak affinity and not specifically to CSA,
this domain has been considered to be part of the true CSA-
binding site. Thus, it was an unexpected discovery that
DBL3X is not necessary for achieving specific high affinity
binding in vitro.
Many of the tested proteins also showed some affinity to
HSPG. However when looking at the raw data in the sensor-
grams it is apparent that the peak response is much lower than
the CSPG binding, indicating that only a subfraction of the
FIGURE 4.ComparingVAR2CSAbinding toCSPGandHSPGusinga solidphasebindingassay.Microtiter plateswere coatedwith either 3g/ml CSPG (Œ),
3 g/ml enzyme treated CSPG (F) or 3 g/ml HSPG (E). A 2-fold dilution series (1.56–100 nM) of each VAR2CSA protein was added to the wells, and an
HRP-conjugated antibody targeting the V5-tag of the proteins was used to detect protein-glycan binding by measuring absorbance at 490 nM. A, NTS-FV2.
B, NTS-DBL3X. C, ID1-DBL4. D, DBL1X-CIDRPAM. E, DBL2X-CIDRPAM. Error bars indicate the standard deviation of triplicate measurements.
VAR2CSA Binds CSAwith the N-terminal Domains
MAY 6, 2011•VOLUME 286•NUMBER 18 JOURNAL OF BIOLOGICAL CHEMISTRY 15915
 at Edinburgh University Library on July 10, 2013http://www.jbc.org/Downloaded from 
proteins binds to HSPG. This prompts the use of homogenous
proteins as well as direct comparative analyses as shown here.
On the basis of our results it seems likely that all four N-ter-
minal domains (DBL1X-ID1-DBL2X-CIDRPAM-DBL3X) form
a binding cleft or pocket in the native VAR2CSAprotein, which
enables specific CSA interactions of high affinity. This kind of
multivalent binding is rather typical for protein-glycan interac-
tions, although there are exceptions. Monovalent protein-gly-
can binding tends to be of relatively low affinity (micro-molar
range) and high avidity is therefore often required for the pro-
tein-glycan interaction to achieve specificity and function in
vivo (1).
The full-length ectodomain of VAR2CSA from the 3D7 par-
asite binds with similar affinity to CSA as the FCR3 variant
analyzed here (7). It has been shown that the overall structure of
VAR2CSA from 3D7 is quite compact, which supports the idea
that the binding site resides in multiple rather than single
domains (7). From a broader perspective, it is interesting that
the receptor binding region ofVAR2CSA from the FCR3 isolate
lies within the N-terminal part of the protein, which corre-
sponds to the conserved domain composition of other PfEMP1
molecules (28). Several domains within this N-terminal region
have been implicated in receptor binding activities, e.g. CD36
binding of CIDR1 domains (29–31), ICAM-1 binding of
DBL-C2 domains (32–34) and binding of the DBL1 domain
to HSPG (35).
It is tempting to speculate that all PfEMP1molecules share a
fundamentally similar mode of binding such that the receptor/
ligand contact zone is always in the semi-conservedN-terminal
part, although the number of domains necessary for high affin-
ity and specificitymay vary. However, considerablymore struc-
tural knowledge about the diverse ectodomains and binding
sites of PfEMP1 proteins are needed to substantiate this
proposal.
The inhibitory function of the VAR2CSA-specific antibodies
generated for this study support the location of the CSA-bind-
ing site in the N-terminal part since antibodies induced against
theNTS-DBL3X protein efficiently abrogate parasite adhesion.
The NTS-DBL3X construct binds specifically and with nano-
molar affinity toCSPG,which suggests that it displays an essen-
tially fully functional receptor binding site and that epitopes
within and around this site are the targets of the inhibitory
antibodies. By contrast, the individual domains DBL2X and
DBL3X both bind poorly to CSPG, probably because many res-
idues necessary for a strong interaction are not present in a
single domain. This would explain why the antigen epitopes
necessary for inducing adhesion-blocking antibodies, which are
probably conformation dependent and contributed by separate
domains, are absent from these constructs. Supporting this
view, pooled antibodies raised against individual domains
(DBL1X, DBL2X, and DBL3X) were not able to inhibit the
interaction betweenVAR2CSA andCSPG.One additional pos-
sible explanation for the lack of adhesion inhibition demon-
strated by pooled IgG could be the absence of antibodies spe-
cific for the CIDRPAM domain, which seems to be an essential
region of the CSA-binding site.
Significantly, our current leading PM vaccine candidate,
which is based on the DBL4 domain including a small interdo-
main region (ID4) from the FCR3 parasite, is not required for a
specific CSA interaction of high affinity in vitro, although this
protein induces inhibitory antibodies that effectively block par-
asite adhesion to CSA (15). Themechanism behind the binding
inhibition induced by immunization with this domain is not
known, but it could be explained by steric hindrance since the
DBL4 domain has been shown by small angle x-ray scattering
FIGURE 5. Levels of anti-VAR2CSA IgG reactivity with the native protein
after immunizationswith recombinant proteins. Bars indicate the relative
reactivity against VAR2CSA expressed on the surface of erythrocytes infected
with the parasite line FCR3 (IEs). The IEs were labeled by purified IgG (0.5
mg/ml) from rats immunized with recombinant VAR2CSA proteins. IgG spe-
cific for the CIDR1 domain from the VAR4 3D7 protein was used as a negative
control. The mean fluorescence intensity (MFI) was recorded from 5000 IEs.
The assay was performed twice with similar results.
FIGURE6. Inhibitionofparasitebinding toCSPGbyVAR2CSA-specific IgG
induced by recombinant proteins. Bars indicate FCR3 P. falciparum-in-
fected erythrocytes (IEs) binding to CSPG, after incubation with VAR2CSA-
specific IgG and washing, as a percentage of binding by the positive control
(binding in cell medium alone). Error bars indicate the standard deviation of
triplicate measurements. The assay was performed with IgG purified from
serum pools of rats immunizedwith the indicated recombinant proteins. IgG
concentrations used: 0.5mg/ml (white bars), 0.1mg/ml (light gray), 0.02 (dark
gray), and 0.004 mg/ml (black). IgG specific for the CIDR1domain from the
VAR4 3D7 protein was used as a negative control. The assay was performed
three times with similar results.
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(SAXS) analysis to be in close proximity to the CSA binding
structure of VAR2CSA.4 These DBL4-ID4 antibodies have
recently proven to be capable of inhibiting the CSA binding of a
panel of P. falciparum parasites isolated from the placenta of
delivering mothers in both Tanzania and Benin (36). Cross-
inhibition is an essential property of any candidate for PM vac-
cine development and by targeting the exact CSA-binding site
it might be possible to induce an even more potent immune
response than has been achieved with the DBL4-ID4 con-
struct. In addition, such a directed antibody response against
the actual receptor binding site would be much more difficult
for the parasite to evade bymutation, following introduction of
an inhibitory PM vaccine. Possibly the DBL4 domain could be
fused to the DBL2X-CIDRPAM to make a stable chimeric pro-
tein, both presenting the minimal binding region as well as the
DBL4 epitopes that has been shown to induce inhibitory
antibodies.
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